Biomarkers of early diagnosis of Parkinson’s disease

The World Health Organization (WHO) has stated that neurodegenerative diseases will be the biggest health problem in the future. Among neurodegenerative diseases, Parkinson’s disease is the second most common after Alzheimer’s disease. Parkinson’s disease (PD) is the most common pathology of a person with movement disorders. Among neurological diseases, it has a high social significance due to the negative effect on the quality of life (early loss of the ability to work, progressive disorders of motor and cognitive skills). With increasing life expectancy, the prevalence of Parkinson’s disease increases. Biological markers of early diagnosis of Parkinson’s disease are being actively studied. The review presents the most clinically significant biological markers for the preclinical diagnosis of Parkinson’s disease. Biomarkers of cerebrospinal fluid, serum biomarkers and biomarkers of other biological fluids in Parkinson's disease are discussed.